Evolution of the Karnosky Performance Status throughout life in glioblastoma patients

Journal of Neuro-Oncology

Volumn 122, Issue 3, 2015, Pages 567-573

  Sacko, Adama ^a   Hou, Miao Miao ^a   Temgoua, Michael ^a   Alkhafaji, Ali ^a   Marantidou, Athina ^a,b   Belin, Catherine ^a   Mandonnet, Emmanuel ^c,d   Ursu, Renata ^a   Doridam, Jennifer ^a,b   Coman, Irène ^a   Levy Piedbois, Christine ^e   Carpentier, Antoine F ^a,b  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Institut de Radiothérapie des Hautes Energies IRHE   (France)

Author keywords

Bevacizumab; Functional independence; Glioblastoma; Karnosky Performance Status (KPS); Radiotherapy; Temozolomide

Indexed keywords

AGE; AGED; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; QUALITY OF LIFE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGE FACTORS; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84939935841     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1749-6     Document Type: Article

References (21)

1. Davis ME, Stoiber AM (2011) Glioblastoma multiforme: enhancing survival and quality of life. Clin J Oncol Nurs 15:291–297
2. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323–331
3. Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, Wong R, de Witte O, Cairncross JG, Efficace F, Mirimanoff RO, Forsyth P, Van Den Bent MJ, Weller M, Bottomley A (2007) The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups and NCIC Clinical Trials Group study. Br J Cancer 97:302–307
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
5. Stark AM, Stepper W, Mehdorn HM (2010) Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC. Eur J Cancer Care 19:39–44
6. Buccheri G, Ferrigno D, Tamburini M (2006) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32:1135–1141
7. Sulter G, Steen C, De Keyser J (1999) Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 30:1538–1541
8. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722
9. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708
10. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943–953
11. Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran WJ, Mehta MP (2011) Validation and simplification of the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) classification for glioblastoma (GBM). Int J Radiat Oncol Biol Phys 81:623–630
12. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
13. Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2015) The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. J Neurooncol 121:359–364
14. Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10:322–328
15. Bussiere M, Hopman W, Day A, Pombo AP, Neves T, Espinosa F (2005) Indicators of functional status for primary malignant brain tumour patients. Can J Neurol Sci 32:50–56
16. Recht L, Glantz M, Chamberlain M, Hsieh CC (2003) Quantitative measurement of quality outcome in malignant glioma patients using an independent living score (ILS). Assessment of a retrospective cohort. J Neurooncol 61:127–136
17. Chaichana KL, Halthore AN, Parker SL, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa A (2011) Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. J Neurosurg 114:604–612
18. Gil-Gil MJ, Mesia C, Rey M, Bruna J (2013) Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 7:123–135
19. Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M (2011) Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 50:630–635
20. Tabouret E, Barrie M, Thiebaut A, Matta M, Boucard C, Autran D, Loundou A, Chinot O (2013) Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen. J Neurooncol 114:191–198
21. Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS (2010) Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15:1329–1334